Despina Yancopoulou
Glyfada, ESYE31, Greece
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
The Complement-Targeted Inhibitor Mini-FH Protects against Experimental Periodontitis via Both C3-Dependent and C3-Independent Mechanisms.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: April 04, 2023
Complement C3 inhibition in severe COVID-19 using compstatin AMY-101.
Journal: Science advances
Published: August 17, 2022
Complement C3 activation in the ICU: Disease and therapy as Bonnie and Clyde.
Journal: Seminars in immunology
Published: July 19, 2022
C3-targeted host-modulation approaches to oral inflammatory conditions.
Journal: Seminars in immunology
Published: June 12, 2022
Phase IIa clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation.
Phase IIa clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation.
Journal: The Journal of clinical investigation
Published: July 06, 2021
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Journal: Clinical immunology (Orlando, Fla.)
Published: September 05, 2020
Author Correction: Complement as a target in COVID-19?
Journal: Nature reviews. Immunology
Published: June 14, 2020
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.
Journal: Clinical immunology (Orlando, Fla.)
Published: April 27, 2020
Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates.
Journal: Clinical immunology (Orlando, Fla.)
Published: March 11, 2020
Complement-Dependent Mechanisms and Interventions in Periodontal Disease.
Journal: Frontiers in immunology
Published: December 02, 2018
Last Updated: 09/26/2026